Monte Rosa Therapeutics announced a $50 million milestone payment from collaborator Novartis regarding a global Phase 2 clinical study of MRT-6160 for Sjogren's disease, validating the QuEEN platform's potential.
Monte Rosa Therapeutics announced a $50 million milestone payment from collaborator Novartis regarding a global Phase 2 clinical study of MRT-6160 for Sjogren's disease, validating the QuEEN platform's potential.